- Identify first-in-class pipeline products with no prior involvement in licensing and co-development
deals that may represent potential investment opportunities.
Table of Contents
1 Table of Contents 2
1.1 List of Tables 3
1.2 List of Figures 3
2 Executive Summary 5
2.1 A Crowded, Competitive Market, with Significant Unmet Needs Remaining 5
2.2 Early-Stage Pipeline Offers Greatest Promise for First-in-Class Innovation 5
2.3 Cytokine and Cytokine Receptors, as well as Protein Kinases, Largely Dominate First-in-Class
Pipeline Products 5
Download sample Copy of This Report at:
http://www.radiantinsights.com/research/frontier-pharma-rheumatoid-
arthritis/request-sample
3 The Case for Innovation 6
3.1 Growing Opportunities for Biologic Products 7
3.2 Diversification of Molecular Targets 7
3.3 Innovative First-in-Class Development Remains Attractive 8
3.4 Regulatory and Reimbursement Policy Shifts Favor First-in-Class Product Innovation 8
3.5 Sustained Innovation 8
3.6 GBI Research Report Guidance 9
4 Clinical and Commercial Landscape 10
4.1 Disease Overview 10
4.2 Disease Symptoms 10
Follow Us: